Effects of statins on restenosis after coronary stent implantation

Angiology

Volumn 58, Issue 1, 2007, Pages 55-60

  Kamishirado, Hirotoshi ^a,d   Inoue, Teruo ^a   Sakuma, Masashi ^b   Tsuda, Tatsuhiro ^c   Hayashi, Terumi ^c   Takayanagi, Kan ^c   Node, Koichi ^a  

^a SAGA UNIVERSITY   (Japan)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c DOKKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d Kamishirado Heart Clinic   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; TICLOPIDINE;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTERY DIAMETER; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY STENT; DRUG EFFECT; DRUG EFFICACY; FEMALE; FOLLOW UP; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERLIPIDEMIA; IN-STENT RESTENOSIS; MAJOR CLINICAL STUDY; MALE; PLEIOTROPY; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

CASE-CONTROL STUDIES; CORONARY ANGIOGRAPHY; CORONARY RESTENOSIS; FATTY ACIDS, MONOUNSATURATED; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; INDOLES; MALE; MIDDLE AGED; MYOCARDIAL REVASCULARIZATION; PRAVASTATIN; RETROSPECTIVE STUDIES; STENTS;

EID: 33847071140     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/0003319706295223     Document Type: Article

References (19)

1. Weintraub WS, Boccuzzi SJ, Klein JL, et al, and the Lovastatin Restenosis Trial Study Group: Lack of effect of lovastatin on restenoses after coronary angioplasty. N Engl J Med 331: 1331-1337, 1994.
2. Bertrand ME, McFadden EP, Fruchart JC, et al: Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty. J Am Coll Cardiol 30: 863-869, 1997.
3. Serruys PW, Foley DP, Jackson G, et al: A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty. Eur Heart J 20: 58-69, 1999.
4. Walter DH, Schachinger V, Elsner M, et al: Effect of statin therapy on restenosis after coronary stent implantation. Am J Cardiol 85: 962-968, 2000.
5. Serruys PW, de Feyter P, Macaya C, et al: Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention. JAMA 287: 3215-3222, 2002.
6. Hoffmann R, Mintz GS, Dussaillant GR, et al: Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. Circulation 94: 1247-1254, 1996.
7. Mintz GS, Popma JJ, Pichard AD, et al: Arterial remodeling after coronary angioplasty: A serial intravascular study. Circulation 94: 35-43, 1996.
8. Inoue T, Hayashi M, Takayanagi K, et al: Lipid-lowering therapy with fluvastatin inhibits oxidative modification of low density lipoprotein and improves vascular endothelial function in hypercholesterolemic patients. Atherosclerosis 160: 369-376, 2002.
9. Schartl M, Bocksch W, Koschyk DH, et al: Use of intravascular ultrasound to compare effects of different strategies of lipid-lowering therapy on plaque volume and composition in patients with coronary artery disease. Circulation 104: 387-392, 2001.
10. Guijarro C, Blanco-Colio LM, Ortego M, et al: 3-hy-droxy-3-methylglutaryl coenzyme A reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. Circ Res 83: 490-500, 1998.
11. Martinez-Gonzalez J, Vinals M, Vidal F, et al: Mevalonate deprivation impairs IGF-1/insulin signaling in human vascular smooth muscle cells. Atherosclerosis 135: 213-223, 1997.
12. Jialal I, Stein D, Balis D, et al: Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 103: 1933-1935, 2001.
13. Gaddam V, Li DV, Mehta JL: Antithrombic effects of atruvastatin: An effect unrelated to lipid lowering. J Cardiovasc Pharmacol Ther 7: 247-253, 2002.
14. Inoue T, Inoue K, Maeda H, et al: Immunological response to oxidized LDL occurs in association with oxidative DNA damage independently of serum LDL levels in dyslipidemic patients. Clin Chim Acta 305: 115-121, 2001.
15. Herd JA, Ballantyne CM, Farmer JA, et al: Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipo-protein and Coronary Atherosclerosis Study [LCAS]). Am J Cardiol 80: 278-286, 1997.
16. Blankenhorn DH, Azen SP, Kramsch DM, et al: Coronary angiographic changes with lovastatin therapy: The monitored atherosclerosis regression study (MARS). Ann Intern Med 119: 969-976, 1993.
17. Waters D, Higginson L, Gladstone P, et al: Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography: The Canadian Coronary Atherosclerosis Intervention Trail (CCAIT). Circulation 89: 959-968, 1994.
18. MAAS Investigators: Effect of simvastatin on coronary atheroma: The Multicentre Anti-Atheroma Study (MAAS). Lancet 344: 633-638, 1994.
19. Bestehorn HP, Rensing UFE, Roskamm H, et al: The effect of simvastatin on progression of coronary artery disease. The multicenter coronary intervention study (CIS). Eur Heart J 18: 226-234, 1997.